Ashish Manne

722 total citations · 1 hit paper
44 papers, 430 citations indexed

About

Ashish Manne is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ashish Manne has authored 44 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 13 papers in Surgery and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ashish Manne's work include Pancreatic and Hepatic Oncology Research (16 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers). Ashish Manne is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers). Ashish Manne collaborates with scholars based in United States, India and United Kingdom. Ashish Manne's co-authors include Laith Abushahin, Carolyn J. Presley, Adithya Chennamadhavuni, Ning Jin, Edward Woods, Allan Tsung, Arjun Mittra, Ashwini Esnakula, Ravi Kumar Paluri and Moh’d Khushman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ashish Manne

38 papers receiving 424 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors

2022 202 citations Adithya Chennamadhavuni, Laith Abushahin et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ashish Manne United States	10	300	107	100	85	57	44	430
Boyang Chang China	12	224 0.7×	90 0.8×	94 0.9×	84 1.0×	142 2.5×	26	458
Laith Abushahin United States	10	409 1.4×	127 1.2×	174 1.7×	65 0.8×	45 0.8×	30	500
Valentina Tateo Italy	10	205 0.7×	106 1.0×	150 1.5×	44 0.5×	114 2.0×	36	437
Shande Tang United States	10	152 0.5×	62 0.6×	97 1.0×	45 0.5×	137 2.4×	15	454
Shinsuke Kanekiyo Japan	15	250 0.8×	138 1.3×	113 1.1×	93 1.1×	163 2.9×	45	530
Shotaro Kato Japan	5	292 1.0×	61 0.6×	136 1.4×	76 0.9×	51 0.9×	14	418
Geoff Chong Australia	9	274 0.9×	105 1.0×	117 1.2×	62 0.7×	64 1.1×	25	414
Tetsuya Urasaki Japan	12	205 0.7×	99 0.9×	107 1.1×	45 0.5×	73 1.3×	53	416
Keita Uchino Japan	12	215 0.7×	59 0.6×	151 1.5×	46 0.5×	86 1.5×	40	357
Elisa Giommoni Italy	14	314 1.0×	66 0.6×	180 1.8×	52 0.6×	158 2.8×	45	527

Countries citing papers authored by Ashish Manne

Since Specialization

Citations

This map shows the geographic impact of Ashish Manne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Manne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Manne more than expected).

Fields of papers citing papers by Ashish Manne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Manne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Manne. The network helps show where Ashish Manne may publish in the future.

Co-authorship network of co-authors of Ashish Manne

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Manne. A scholar is included among the top collaborators of Ashish Manne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Manne. Ashish Manne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manne, Ashish, et al.. (2025). Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies. Cancers. 17(4). 589–589. 1 indexed citations

Klein, Katherine J., Betül Gök Yavuz, Tarık Demir, et al.. (2025). Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma. npj Precision Oncology. 9(1). 60–60. 2 indexed citations

Elsaid, Mohamed I. & Ashish Manne. (2025). Novel Therapeutics for Hepatocellular Carcinoma. Clinics in Liver Disease. 29(4). 673–696.

Elsaid, Mohamed I., Alexa Meara, Dwight H. Owen, et al.. (2024). Risk and impacts of drug-induced liver injury (DILI) due to immune-checkpoint inhibitors (ICI) on overall survival in patients with newly diagnosed cancer: A retrospective cohort study.. Journal of Clinical Oncology. 42(16_suppl). 12049–12049. 1 indexed citations

Bajpai, Prachi, Farrukh Afaq, Sameer Al Diffalha, et al.. (2024). Abstract 585: Regorafenib antitumor immune response is enhanced by a novel drug combination in CRC syngeneic model. Cancer Research. 84(6_Supplement). 585–585.

Agarwal, Sumit, Farrukh Afaq, Sameer Al Diffalha, et al.. (2024). Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer. Journal of Experimental & Clinical Cancer Research. 43(1). 192–192. 9 indexed citations

Korman, Abraham M., et al.. (2024). Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature. Frontiers in Medicine. 11. 1334718–1334718. 5 indexed citations

Cloyd, Jordan M., Ashish Manne, Kenneth L. Pitter, et al.. (2023). Treatment Patterns and Outcomes for Patients with Ampullary Carcinoma Who Do Not Undergo Surgery. Cancers. 15(14). 3727–3727. 2 indexed citations

Manne, Ashish, Lianbo Yu, Phil A. Hart, Allan Tsung, & Ashwini Esnakula. (2023). Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma. Cancers. 15(19). 4832–4832.

10.

Bath, Natalie, et al.. (2023). Management of locally advanced intrahepatic cholangiocarcinoma: a narrative review. Chinese Clinical Oncology. 12(2). 15–15. 7 indexed citations

11.

Ejaz, Aslam, et al.. (2023). Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?. International Journal of Molecular Sciences. 24(18). 14231–14231. 1 indexed citations

12.

Rahman, Shafia, et al.. (2023). Understanding the Clinical Significance of MUC5AC in Biliary Tract Cancers. Cancers. 15(2). 433–433. 3 indexed citations

13.

Ruff, Samantha M., Ashish Manne, Jordan M. Cloyd, et al.. (2023). Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology. 30(6). 5863–5875. 12 indexed citations

14.

Chennamadhavuni, Adithya, Laith Abushahin, Ning Jin, Carolyn J. Presley, & Ashish Manne. (2022). Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Frontiers in Immunology. 13. 779691–779691. 202 indexed citations breakdown →

15.

Manne, Ashish, Ashwini Esnakula, Laith Abushahin, & Allan Tsung. (2021). Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Cancers. 13(12). 3059–3059. 19 indexed citations

16.

Manne, Ashish, et al.. (2021). Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors. Journal of Clinical Medicine Research. 13(5). 268–275. 11 indexed citations

17.

Manne, Ashish, et al.. (2020). Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncology Reviews. 14(2). 515–515. 3 indexed citations

18.

Campos, Yolanda, et al.. (2019). Vitamin B12 deficiency presenting as pseudo-thrombotic microangiopathy: a case report and literature review. SHILAP Revista de lepidopterología. 7 indexed citations

19.

Jacob, Rojymon, et al.. (2019). Therapeutic options for ampullary carcinomas. A review. Oncology Reviews. 13(2). 440–440. 10 indexed citations

20.

Manne, Ashish, et al.. (2015). Obesity and Outcome of Crohn’s Associated Perianal Fistula Surgery: A Case-Control Study. Gastroenterology Research. 8(6). 291–295. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact